Incidence of non-hodgkin lymphoma in kidney and heart transplant recipients

The Lancet

Volumn 342, Issue 8886-8887, 1993, Pages 1514-1516

  Opelz, G ^a   Henderson, R ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; OKT 3; STEROID; THYMOCYTE ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GERMANY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RISK ASSESSMENT;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; EUROPE; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGE; MUROMONAB-CD3; NORTH AMERICA; RISK; SUPPORT, NON-U.S. GOV'T;

EID: 0027501649     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)80084-4     Document Type: Article

References (10)

1. Malignant lymphomas in transplantation patients
2. Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft
3. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant postransplant lymphoproliferative disorder?
4. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients
5. The changing pattern of posttransplant malignancies
6. Optimal use of cyclosporine in cinical organ transplantation
7. Cyclosporine abrogates virus-specific T cell control of EBV-induced B-cell lympho-proliferation